Sentinel node evaluation in prostate cancer

Narayanan, Ramkishen; Wilson, Timothy G.

doi:10.1007/s10585-018-9936-4

Cited by 14 publications

(8 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For three-dimensional quantitative non-invasive in vivo visualization of the TDLNs [ 6 , 7 ] by functional 18 F-FDG-PET ( 18 F-FDG: 181.1 g mol −1 ), we used a dedicated small animal microPET scanner (Siemens Heathineers, Knoxville, TN).…”

Section: Methodsmentioning

confidence: 99%

Preclinical Identification Of Tumor-Draining Lymph Nodes Using a Multimodal Non-invasive In vivo Imaging Approach

et al. 2023

View full text Add to dashboard Cite

Purpose Resection of the tumor-draining lymph -node (TDLN) represents a standard method to identify metastasis for several malignancies. Interestingly, recent preclinical studies indicate that TDLN resection diminishes the efficacy of immune checkpoint inhibitor-based cancer immunotherapies. Thus, accurate preclinical identification of TDLNs is pivotal to uncovering the underlying immunological mechanisms. Therefore, we validated preclinically, and clinically available non-invasive in vivo imaging approaches for precise TDLN identification. Procedures For visualization of the lymphatic drainage into the TDLNs by non-invasive in vivo optical imaging, we injected the optical imaging contrast agents Patent Blue V (582.7 g mol−1) and IRDye® 800CW polyethylene glycol (PEG; 25,000–60,000 g mol−1), subcutaneously (s.c.) in close proximity to MC38 adenocarcinomas at the right flank of experimental mice. For determination of the lymphatic drainage and the glucose metabolism in TDLNs by non-invasive in vivo PET/magnetic resonance imaging (PET/MRI), we injected the positron emission tomography (PET) tracer (2-deoxy-2[18F]fluoro-D-glucose (18F-FDG) [181.1 g mol−1]) in a similar manner. For ex vivo cross-correlation, we isolated TDLNs and contralateral nontumor-draining lymph nodes (NTDLNs) and performed optical imaging, biodistribution, and autoradiography analysis. Results The clinically well-established Patent Blue V was superior for intraoperative macroscopic identification of the TDLNs compared with IRDye® 800CW PEG but was not sensitive enough for non-invasive in vivo detection by optical imaging. Ex vivo Patent Blue V biodistribution analysis clearly identified the right accessory axillary and the proper axillary lymph node (LN) as TDLNs, whereas ex vivo IRDye® 800CW PEG completely failed. In contrast, functional non-invasive in vivo18F-FDG PET/MRI identified a significantly elevated uptake exclusively within the ipsilateral accessory axillary TDLN of experimental mice and was able to differentiate between the accessory axillary and the proper LN. Ex vivo biodistribution and autoradiography confirmed our in vivo18F-FDG PET/MRI results. Conclusions When taken together, our results demonstrate the feasibility of 18F-FDG-PET/MRI as a valid method for non-invasive in vivo, intraoperative, and ex vivo identification of the lymphatic drainage and glucose metabolism within the TDLNs. In addition, using Patent Blue V provides additive value for the macroscopic localization of the lymphatic drainage both visually and by ex vivo optical imaging analysis. Thus, both methods are valuable, easy to implement, and cost-effective for preclinical identification of the TDLN.

show abstract

Section: Methodsmentioning

confidence: 99%

Preclinical Identification Of Tumor-Draining Lymph Nodes Using a Multimodal Non-invasive In vivo Imaging Approach

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Therefore, SLND, already a first choice procedure in melanoma, breast and penile cancers, is taken into consideration as an alternative [89]. According to the concept of metastatic spread of the tumor along the lymph drainage pathways, an assumption can be made that the absence of cancer invasion in the sentinel nodes is coequal with the lack of metastasis in other LNs [90]. The implementation of SLND would ideally prevent patients with PCa from overtreatment them with ePLND [91].…”

Section: New Perspectives For Plndmentioning

confidence: 99%

Utility of Lymphadenectomy in Prostate Cancer: Where Do We Stand?

Małkiewicz

Kiełb

Karwacki

et al. 2022

JCM

View full text Add to dashboard Cite

The purpose of this review is to summarize the current knowledge on lymph node dissection (LND) in prostate cancer (PCa) patients undergoing radical prostatectomy (RP). Despite a growing body of evidence, the utility and therapeutic and prognostic value of such an approach, as well as the optimal extent of LND, remain unsolved issues. Although LND is the most accurate staging procedure, the direct therapeutic effect is still not evident from the current literature, which limits the possibility of establishing clear recommendations. This indicates the need for further robust and adequately designed high-quality clinical trials.

show abstract

“…Sentinel lymph node biopsy (SLNB) theoretically detects the first LNs in the chain of lymphatic drainage of the primary tumor [ 221 ]. The expected benefits of SLNB are the reduction in the surgical time, cost, and potential complications, as well as an improvement of the staging by identifying unusual drainage roots [ 221 , 222 ]. SLNB was used in PCa in 1999 [ 223 ] and proved to be a valid method for N-staging with high diagnostic accuracy [ 224 , 225 , 226 ].…”

Section: Sentinel Lymph Node Biopsymentioning

confidence: 99%

Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends

Manafi‐Farid

Ranjbar

Araghi

et al. 2021

Cancers

View full text Add to dashboard Cite

Accurate primary staging is the cornerstone in all malignancies. Different morphological imaging modalities are employed in the evaluation of prostate cancer (PCa). Regardless of all developments in imaging, invasive histopathologic evaluation is still the standard method for the detection and staging of the primary PCa. Magnetic resonance imaging (MRI) and computed tomography (CT) play crucial roles; however, functional imaging provides additional valuable information, and it is gaining ever-growing acceptance in the management of PCa. Targeted imaging with different radiotracers has remarkably evolved in the past two decades. [111In]In-capromab pendetide scintigraphy was a new approach in the management of PCa. Afterwards, positron emission tomography (PET) tracers such as [11C/18F]choline and [11C]acetate were developed. Nevertheless, none found a role in the primary staging. By introduction of the highly sensitive small molecule prostate-specific membrane antigen (PSMA) PET/CT, as well as recent developments in MRI and hybrid PET/MRI systems, non-invasive staging of PCa is being contemplated. Several studies investigated the role of these sophisticated modalities in the primary staging of PCa, showing promising results. Here, we recapitulate the role of targeted functional imaging. We briefly mention the most popular radiotracers, their diagnostic accuracy in the primary staging of PCa, and impact on patient management.

show abstract

Sentinel node evaluation in prostate cancer

Cited by 14 publications

References 117 publications

Preclinical Identification Of Tumor-Draining Lymph Nodes Using a Multimodal Non-invasive In vivo Imaging Approach

Preclinical Identification Of Tumor-Draining Lymph Nodes Using a Multimodal Non-invasive In vivo Imaging Approach

Utility of Lymphadenectomy in Prostate Cancer: Where Do We Stand?

Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends

Contact Info

Product

Resources

About